Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cytosorbents Corp CTSO

Healthcare Medical Devices
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive... see more

Recent & Breaking News (NDAQ:CTSO)

CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress

PR Newswire April 28, 2022

CytoSorbents to Report First Quarter 2022 Operating and Financial Results

PR Newswire April 19, 2022

CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World

PR Newswire April 14, 2022

CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program

PR Newswire April 7, 2022

CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors

PR Newswire April 5, 2022

CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)

PR Newswire March 17, 2022

CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook

PR Newswire March 8, 2022

CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

PR Newswire February 8, 2022

CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences

PR Newswire February 3, 2022

First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock

PR Newswire February 1, 2022

New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology

PR Newswire January 24, 2022

CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

PR Newswire January 18, 2022

CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

PR Newswire December 21, 2021

CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

PR Newswire December 20, 2021

CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference

PR Newswire November 15, 2021

CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results

PR Newswire November 4, 2021

CytoSorbents Comments on REMOVE Study Presentation

PR Newswire October 20, 2021

First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR(TM) Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

PR Newswire October 14, 2021

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery

PR Newswire October 12, 2021

CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance

PR Newswire October 12, 2021